Semin Neurol 2019; 39(05): 596-607
DOI: 10.1055/s-0039-1693008
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Jeffrey Shije
1   Peripheral Neuropathy Center, Neurological Institute, Columbia University, New York, New York
,
Thomas H. Brannagan III
1   Peripheral Neuropathy Center, Neurological Institute, Columbia University, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
22 October 2019 (online)

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a relatively common autoimmune disorder affecting the peripheral nerves and nerve roots, often causing progressive or recurrent weakness with diminished reflexes. Electrodiagnostic (EDx) studies, cerebral spinal fluid (CSF) analysis, and nerve biopsy may help provide supportive evidence for the diagnosis. Most cases have a favorable response to one of the three first-line treatments: corticosteroids, IV immunoglobulin (IVIG) and plasmapheresis. Responses to these treatments may vary among individual patients. There is evidence that a small percentage of CIDP patients with IgG class 4 (IgG4) autoantibodies to paranodal proteins have characteristic clinical features and poorer response to IVIG. Chemotherapy and other immunomodulatory agents, as well as hematopoietic stem cell transplantation, may be considered in refractory cases. The degree of disability varies, and most patients require ongoing treatment to maintain stable disease, although long-term remission or cure may be achieved in some patients.

 
  • References

  • 1 Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958; 81 (02) 157-192
  • 2 Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50 (11) 621-637
  • 3 McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110 (Pt 6): 1617-1630
  • 4 Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46 (08) 878-884
  • 5 Hattori N, Misu K, Koike H. , et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184 (01) 57-63
  • 6 Querol L, Nogales-Gadea G, Rojas-Garcia R. , et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2014; 82 (10) 879-886
  • 7 Ogata H, Yamasaki R, Hiwatashi A. , et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015; 2 (10) 960-971
  • 8 Devaux JJ, Miura Y, Fukami Y. , et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 86 (09) 800-807
  • 9 Kadoya M, Kaida K, Koike H. , et al. IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol 2016; 301: 16-22
  • 10 Doppler K, Appeltshauser L, Wilhelmi K. , et al. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 2015; 86 (07) 720-728
  • 11 Miura Y, Devaux JJ, Fukami Y. , et al; CNTN1-CIDP Study Group. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 2015; 138 (Pt 6): 1484-1491
  • 12 Henderson RD, Sandroni P, Wijdicks EFM. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol 2005; 252 (10) 1235-1237
  • 13 Macia F, Le Masson G, Rouanet-Larriviere M. , et al. A prospective evaluation of phrenic nerve conduction in multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2003; 28 (03) 319-323
  • 14 Ingall TJ, McLeod JG, Tamura N. Autonomic function and unmyelinated fibers in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1990; 13 (01) 70-76
  • 15 Lyu R-K, Tang L-M, Wu Y-R, Chen S-T. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002; 26 (05) 669-672
  • 16 Stamboulis E, Katsaros N, Koutsis G, Iakovidou H, Giannakopoulou A, Simintzi I. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2006; 33 (01) 78-84
  • 17 Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 50 (04) 1179-1182
  • 18 Figueroa JJ, Dyck PJB, Laughlin RS. , et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78 (10) 702-708
  • 19 Ruts L, Drenthen J, Jacobs BC, van Doorn PA. ; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010; 74 (21) 1680-1686
  • 20 Laughlin RS, Dyck PJB, Melton III LJ, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73 (01) 39-45
  • 21 Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66 (05) 677-680
  • 22 Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8 (02) 157-165
  • 23 Kusumi M, Nakashima K, Nakayama H, Takahashi K. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci 1995; 49 (03) 169-174
  • 24 Chiò A, Cocito D, Bottacchi E. , et al; PARCIDP. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78 (12) 1349-1353
  • 25 McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46 (06) 910-913
  • 26 Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39 (04) 432-438
  • 27 Mahdi-Rogers M, Hughes RAC. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014; 21 (01) 28-33
  • 28 Larsen JP, Kvåle G, Nyland H. Epidemiology of the Guillain-Barré syndrome in the county of Hordaland, Western Norway. Acta Neurol Scand 1985; 71 (01) 43-47
  • 29 Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996; 19 (04) 474-487
  • 30 Schneider-Hohendorf T, Schwab N, Uçeyler N, Göbel K, Sommer C, Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78 (06) 402-408
  • 31 Misawa S, Kuwabara S, Mori M, Kawaguchi N, Yoshiyama Y, Hattori T. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 2001; 56 (05) 666-669
  • 32 Beppu M, Sawai S, Misawa S. , et al. Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2015; 279: 7-10
  • 33 Rentzos M, Angeli AV, Rombos A. , et al. Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients. Neurol Res 2012; 34 (09) 842-846
  • 34 Mei F-J, Ishizu T, Murai H. , et al. Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. J Neurol Sci 2005; 228 (01) 75-85
  • 35 Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma and IL-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci 1999; 163 (01) 47-52
  • 36 Salomon B, Rhee L, Bour-Jordan H. , et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 2001; 194 (05) 677-684
  • 37 Harvey GK, Pollard JD, Schindhelm K, Antony J. Chronic experimental allergic neuritis. An electrophysiological and histological study in the rabbit. J Neurol Sci 1987; 81 (2-3): 215-225
  • 38 McCombe PA, van der Kreek SA, Pender MP. The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. J Neuroimmunol 1990; 28 (02) 131-140
  • 39 Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50 (03) 286-292
  • 40 Meléndez-Vásquez C, Redford J, Choudhary PP. , et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1997; 73 (1-2): 124-134
  • 41 Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 2000; 104 (02) 139-146
  • 42 Sanvito L, Makowska A, Mahdi-Rogers M. , et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2009; 80 (03) 333-338
  • 43 Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RA. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 46 (1-2): 245-251
  • 44 Vural A, Doppler K, Meinl E. Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol 2018; 9: 1029
  • 45 Albers JW, Kelly Jr JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12 (06) 435-451
  • 46 Cornblath DR, Asbury AK, Albers JW. , et al. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41 (05) 617-618
  • 47 Bromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991; 14 (10) 968-976
  • 48 Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24 (03) 311-324
  • 49 Latov N. Diagnosis of CIDP. Neurology 2002; 59 (12) (Suppl. 06) S2-S6
  • 50 Nicolas G, Maisonobe T, Le Forestier N, Léger J-M, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002; 25 (01) 26-30
  • 51 Hughes R, Bensa S, Willison H. , et al; Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50 (02) 195-201
  • 52 Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002; 59 (10) 1526-1532
  • 53 Magda P, Latov N, Brannagan III TH, Weimer LH, Chin RL, Sander HW. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2003; 60 (12) 1755-1759
  • 54 Berger AR, Bradley WG, Brannagan TH. , et al; Neuropathy Association, Medical Advisory Committee. Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2003; 8 (04) 282-284
  • 55 Van Schaik IN, Léger JM, Nobile-Orazio E. , et al; Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 2010; 15 (04) 295-301
  • 56 Breiner A, Brannagan III TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014; 50 (01) 40-46
  • 57 Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32 (09) 958-964
  • 58 Viala K, Renié L, Maisonobe T. , et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; 127 (Pt 9): 2010-2017
  • 59 Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54 (03) 615-620
  • 60 Leitch MM, Sherman WH, Brannagan III TH. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide. Muscle Nerve 2013; 47 (02) 292-296
  • 61 Gable KL, Afshari Z, Sufit RL, Allen JA. Distal acquired demyelinating symmetric neuropathy after vaccination. J Clin Neuromuscul Dis 2013; 14 (03) 117-122
  • 62 Dyck PJ, Dyck PJB. Atypical varieties of chronic inflammatory demyelinating neuropathies. Lancet 2000; 355 (9212): 1293-1294
  • 63 Larue S, Bombelli F, Viala K. , et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011; 18 (06) 899-905
  • 64 Oh SJ, Joy JL, Kuruoglu R. “Chronic sensory demyelinating neuropathy”: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992; 55 (08) 677-680
  • 65 Chin RL, Latov N, Sander HW. , et al. Sensory CIDP presenting as cryptogenic sensory polyneuropathy. J Peripher Nerv Syst 2004; 9 (03) 132-137
  • 66 Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as “chronic sensory demyelinating polyneuropathy”. Muscle Nerve 1995; 18 (04) 440-444
  • 67 van Dijk GW, Notermans NC, Franssen H, Wokke JHJ. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol 1999; 246 (12) 1134-1139
  • 68 Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004; 63 (09) 1662-1669
  • 69 Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002; 59 (05) 758-765
  • 70 Chiò A, Plano F, Calvo A, Leone M, Mutani R, Cocito D. ; Piemonte and Valle D'Aosta Registry for CIDP (PARCIDP). Comorbidity between CIDP and diabetes mellitus: only a matter of chance?. Eur J Neurol 2009; 16 (06) 752-754
  • 71 Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000; 23 (01) 37-43
  • 72 Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry 2009; 80 (01) 70-73
  • 73 Cornblath DR. Treatment of the neuromuscular complications of human immunodeficiency virus infection. Ann Neurol 1988; 23 (Suppl): S88-S91
  • 74 Ferrari S, Vento S, Monaco S. , et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc 2006; 81 (02) 213-219
  • 75 Przedborski S, Liesnard C, Voordecker P. , et al. Inflammatory demyelinating polyradiculoneuropathy associated with human immunodeficiency virus infection. J Neurol 1988; 235 (06) 359-361
  • 76 Moodley K, Bill PLA, Patel VB. A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients. Neurol Neuroimmunol Neuroinflamm 2016; 4 (02) e315
  • 77 Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48 (02) 321-328
  • 78 Nobile-Orazio E, Latov N, Hays AP. , et al. Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology 1984; 34 (02) 218-221
  • 79 Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 1988; 3 (04) 301-332
  • 80 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000; 123 (Pt 4): 710-717
  • 81 Renaud S, Gregor M, Fuhr P. , et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27 (05) 611-615
  • 82 Nobile-Orazio E, Manfredini E, Carpo M. , et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36 (03) 416-424
  • 83 Garcia-Santibanez R, Zaidman CM, Sommerville RB. , et al. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). J Neurol 2018; 265 (06) 1402-1409
  • 84 Carpo M, Meucci N, Allaria S. , et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci 2000; 176 (02) 144-150
  • 85 Guo X, Qin X, Zhang Y, Huang C, Yu G. Electrophysiological features of POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Clin Neurosci 2014; 21 (04) 587-590
  • 86 Lozeron P, Mariani L-L, Dodet P. , et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 2018; 91 (02) e143-e152
  • 87 Bird SJ, Sladky JT. Corticosteroid-responsive dominantly inherited neuropathy in childhood. Neurology 1991; 41 (03) 437-439
  • 88 Donaghy M, Sisodiya SM, Kennett R, McDonald B, Haites N, Bell C. Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation. J Neurol Neurosurg Psychiatry 2000; 69 (06) 799-805
  • 89 Ginsberg L, Malik O, Kenton AR. , et al. Coexistent hereditary and inflammatory neuropathy. Brain 2004; 127 (Pt 1): 193-202
  • 90 Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982; 32 (06) 592-596
  • 91 Rechthand E, Cornblath DR, Stern BJ, Meyerhoff JO. Chronic demyelinating polyneuropathy in systemic lupus erythematosus. Neurology 1984; 34 (10) 1375-1377
  • 92 Gondim FAA, Brannagan III TH, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 2005; 128 (Pt 4): 867-879
  • 93 Wong AHY, Kokubun N, Fukami Y, Miyaji K, Yuki N. Chronic inflammatory demyelinating polyneuropathy with membranous nephropathy. J Peripher Nerv Syst 2015; 20 (01) 63-66
  • 94 Echaniz-Laguna A, de Séze J, Chanson J-B. Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. J Neurol Neurosurg Psychiatry 2012; 83 (07) 699-705
  • 95 Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review. Muscle Nerve 2018; 57 (06) 875-883
  • 96 Alshekhlee A, Basiri K, Miles JD, Ahmad SA, Katirji B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-α antagonists. Muscle Nerve 2010; 41 (05) 723-727
  • 97 Kao JC, Liao B, Markovic SN. , et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 2017; 74 (10) 1216-1222
  • 98 Kolb NA, Trevino CR, Waheed W. , et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve 2018; 58: 10-22
  • 99 Mathis S, Magy L, Diallo L, Boukhris S, Vallat J-M. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012; 45 (01) 26-31
  • 100 Dyck PJ, O'Brien PC, Oviatt KF. , et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11 (02) 136-141
  • 101 Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005; 62 (02) 249-254
  • 102 Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008; 65 (11) 1460-1464
  • 103 van Schaik IN, Eftimov F, van Doorn PA. , et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9 (03) 245-253
  • 104 Nobile-Orazio E, Cocito D, Jann S. , et al; IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11 (06) 493-502
  • 105 Mendell JR, Barohn RJ, Freimer ML. , et al; Working Group on Peripheral Neuropathy. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56 (04) 445-449
  • 106 Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119 (Pt 4): 1067-1077
  • 107 Hughes RAC, Donofrio P, Bril V. , et al; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7 (02) 136-144
  • 108 Kaplan A, Brannagan III TH. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2017; 55 (04) 476-482
  • 109 Brannagan III TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47 (03) 674-677
  • 110 Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29 (03) 173-184
  • 111 Kuitwaard K, van den Berg LH, Vermeulen M. , et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010; 81 (12) 1374-1379
  • 112 Gallia F, Balducci C, Nobile-Orazio E. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies. J Peripher Nerv Syst 2016; 21 (02) 82-84
  • 113 Markvardsen LH, Sindrup SH, Christiansen I, Olsen NK, Jakobsen J, Andersen H. ; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol 2017; 24 (02) 412-418
  • 114 Markvardsen LH, Debost J-C, Harbo T. , et al; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013; 20 (05) 836-842
  • 115 Markvardsen LH, Harbo T, Sindrup SH, Christiansen I, Andersen H, Jakobsen J. ; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2014; 21 (12) 1465-1470
  • 116 van Schaik IN, Bril V, van Geloven N. , et al; PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2018; 17 (01) 35-46
  • 117 Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis. Muscle Nerve 2017; 55 (06) 802-809
  • 118 Dyck PJ, Litchy WJ, Kratz KM. , et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36 (06) 838-845
  • 119 Hahn AF, Bolton CF, Pillay N. , et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119 (Pt 4): 1055-1066
  • 120 Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2017; 11: CD002062
  • 121 Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013; 12 (12) CD001797
  • 122 Mehndiratta MM, Hughes RAC, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2015; 8 (08) CD003906
  • 123 Cocito D, Paolasso I, Antonini G. , et al; Italian Network for CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17 (02) 289-294
  • 124 Cocito D, Grimaldi S, Paolasso I. , et al; Italian Network for CIDP Register. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011; 18 (12) 1417-1421
  • 125 Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry 2010; 81 (06) 634-636
  • 126 Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RA. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 2006; 77 (04) 544-547
  • 127 Gladstone DE, Prestrud AA, Brannagan III TH. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005; 10 (01) 11-16
  • 128 Matsuda M, Hoshi K, Gono T, Morita H, Ikeda S. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004; 224 (1-2): 29-35
  • 129 Odaka M, Tatsumoto M, Susuki K, Hirata K, Yuki N. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005; 76 (08) 1115-1120
  • 130 Gorson KC, Allam G, Simovic D, Ropper AH. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 1997; 48 (03) 777-780
  • 131 Pavesi G, Cattaneo L, Marbini A, Gemignani F, Mancia D. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002; 249 (06) 777-779
  • 132 Vallat J-M, Hahn AF, Léger J-M. , et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003; 60 (08) (Suppl. 03) S23-S28
  • 133 Benedetti L, Briani C, Franciotta D. , et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82 (03) 306-308
  • 134 Roux T, Debs R, Maisonobe T. , et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. J Peripher Nerv Syst 2018; 23 (04) 235-240
  • 135 Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35 (08) 1173-1176
  • 136 Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53 (01) 57-61
  • 137 Hughes RAC, Gorson KC, Cros D. , et al; Avonex CIDP Study Group. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74 (08) 651-657
  • 138 Mahdi-Rogers M, Rutterford C, Hughes RAC. , et al; RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8 (02) 158-164
  • 139 Hughes R, Dalakas MC, Merkies I. , et al; FORCIDP Trial Investigators. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol 2018; 17 (08) 689-698
  • 140 Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2017; 5: CD003280
  • 141 Marsh EA, Hirst CL, Llewelyn JG. , et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257 (06) 913-919
  • 142 Ahlmén J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998; 30 (08) 4194
  • 143 Renard D, Gauthier T, Venetz J-P, Buclin T, Kuntzer T. Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. Clin Kidney J 2012; 5 (04) 323-326
  • 144 Chin RL, Sherman WH, Sander HW, Hays AP, Latov N. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003; 210 (1-2): 19-21
  • 145 Oyama Y, Sufit R, Loh Y. , et al. Nonmyeloablative autologous hematopoietic stem celltransplantation for refractory CIDP. Neurology 2007; 69 (18) 1802-1803
  • 146 Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 72 (01) 127-128
  • 147 Vermeulen M, van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J Neurol Neurosurg Psychiatry 2007; 78 (10) 1154
  • 148 Press R, Askmark H, Svenningsson A. , et al. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry 2014; 85 (06) 618-624
  • 149 Garg N, Park SB, Yiannikas C. , et al. Neurofascin-155 IGG4 neuropathy: pathophysiological insights, spectrum of clinical severity and response to treatment. Muscle Nerve 2018; 57 (05) 848-851
  • 150 Querol L, Nogales-Gadea G, Rojas-Garcia R. , et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013; 73 (03) 370-380
  • 151 Burnor E, Yang L, Zhou H. , et al. Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology 2018; 90 (01) e31-e38
  • 152 Querol L, Rojas-García R, Diaz-Manera J. , et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015; 2 (05) e149
  • 153 Gorson KC, van Schaik IN, Merkies ISJ. , et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15 (04) 326-333
  • 154 Remenyi P, Masszi T, Borbenyi Z. , et al. CIDP cured by allogenic hematopoietic stem cell transplantation. Eur J Neurol 2007; 14 (08) e1-e2